Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy.

British journal of haematology - 1 Jul 2010

Pitini Vincenzo, Sturniolo Giuseppe, Arrigo Carmela, Leonardi Silvana, Pino Salvatrice, Altavilla Giuseppe

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Murine-Derived
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Lymphoma, B-Cell

Share to Rituximab

Share to Virus Activation

Source

Identifiers

PMID: 20230413
DOI: 10.1111/j.1365-2141.2010.08154.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy.PMID 20230413Read ↗

Do hepatitis C Virus genotypes influence liver dysfunction following rituximab-containing regimens in patients with diffuse large B cell lymphoma?Semantic proximity Read ↗

Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab.Semantic proximity Read ↗

Rituximab is effective for human herpesvirus-8-negative primary effusion lymphoma with CD20 phenotype associated hepatitis C virus-related liver cirrhosis.Semantic proximity Read ↗

Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.Semantic proximity Read ↗

Hepatitis C Virus-Associated Non-Hodgkin Lymphomas: Biology, Epidemiology, and Treatment.Semantic proximity Read ↗

Elbasvir/Grazoprevir combination therapy in a B-NHL patient with HCV genotype 1 infection.Semantic proximity Read ↗

Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity.Semantic proximity Read ↗

Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab.Semantic proximity Read ↗

Risk of hepatitis B virus reactivation in B-cell malignancies treated with BTK inhibitorsSemantic proximity Read ↗

Hepatitis C Virus-Associated B-Cell Non-Hodgkin's Lymphoma: Clinical and Therapeutic Challenges.Semantic proximity Read ↗

The genotype of the hepatitis C virus in patients with HCV-related B cell non-Hodgkin's lymphoma.Semantic proximity Read ↗

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.